Refractory wounds (RWs) are a common and severe complication of many diseases; however, the existing therapeutic methods are unsatisfactory in clinical practice. Here, we observed significant downregulation of the hepatocyte growth factor (HGF) in plasma samples from patients with autoimmune diseases. We used electroporation to deliver a plasmid containing HGF to induce its overexpression on mesenchymal stromal cells (MSCHGF ) and loaded them into an injectable hydrogel to treat RWs in patients with clinical autoimmunity. The MSCHGF exhibited stable HGF expression and secretion. In addition, they displayed a self-reinforcing loop, enhanced migration, and improved anti-apoptosis capacity via the autocrine activation of the c-Met-mediated phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) signaling pathway. Furthermore, the HGF (as well as other bioactive factors) secreted from the MSCHGF significantly augmented the migration and angiopoiesis of vascular endothelial cells, decreased the cellular inflammation of macrophages, and improved extracellular matrix remodeling in fibroblasts. According to these features, we demonstrated that the MSCHGF-loaded injectable hydrogel boosted cellular functions and afforded a long-acting healing efficacy in the treatment of clinical autoimmune patients with RWs. Therefore, the genetically engineered MSCHGF and their dispersed hydrogel system will have clinical significance for wound therapy. (c) 2025 The Authors. Published by Elsevier B.V. and Science China Press. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
[1]Nanjing Univ, Nanjing Drum Tower Hosp, Dept Rheumatol & Immunol, Affiliated Hosp,Med Sch, Nanjing 210002, Peoples R China.
[2]Southeast Univ, Sch Biol Sci & Med Engn, Nanjing 210096, Peoples R China.
(8.0+极速模式)